Karthick Mayilsamy

This study identifies the CCL20-CCR6 axis as a driver of chronic neuroinflammation after rTBI and shows that shRNA targeting this axis reduces synaptic loss and improves behavioral outcomes.

This study identifies CCL20-CCR6 signaling as a prognostic biomarker and therapeutic target in temozolomide-resistant glioblastoma, showing that its inhibition enhances treatment response and induces tumor cell death.

This study develops glomerulus-targeted nanotherapy using collagen IV-α3 binding peptides to improve renal function and reduce inflammation in lupus nephritis.

This paper introduces a deep learning framework for automated segmentation and classification of traumatic brain injury using GFAP and IBA1 biomarkers, showing improved performance over manual methods.

This study shows that inhibiting SARS-CoV-2 spike protein palmitoylation reduces virus infectivity by disrupting trimerization and membrane fusion.